These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 16463553)

  • 21. Postmenopausal Osteoporosis.
    Black DM; Rosen CJ
    N Engl J Med; 2016 May; 374(21):2096-7. PubMed ID: 27223157
    [No Abstract]   [Full Text] [Related]  

  • 22. Sustained vertebral antifracture efficacy of oral anti-osteoporotic therapies in postmenopausal osteoporosis.
    Brandi ML
    Curr Med Res Opin; 2010 Nov; 26(11):2553-63. PubMed ID: 20858031
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Under-use of bisphosphonates in rural elderly women who have sustained fractures.
    Naunton M; Peterson G; Jones G
    Aust J Rural Health; 2006 Dec; 14(6):286. PubMed ID: 17121511
    [No Abstract]   [Full Text] [Related]  

  • 24. Postmenopausal Osteoporosis.
    Michaëlsson K; Aspenberg P
    N Engl J Med; 2016 May; 374(21):2095. PubMed ID: 27223158
    [No Abstract]   [Full Text] [Related]  

  • 25. Compliance with treatment for osteoporosis.
    Cooper A
    Lancet; 2006 Nov; 368(9548):1648. PubMed ID: 17098078
    [No Abstract]   [Full Text] [Related]  

  • 26. Bisphosphonates for osteoporosis.
    Favus MJ
    N Engl J Med; 2010 Nov; 363(21):2027-35. PubMed ID: 21083387
    [No Abstract]   [Full Text] [Related]  

  • 27. Yearly zoledronic acid in postmenopausal osteoporosis.
    Najib MA; Aziz I
    N Engl J Med; 2007 Aug; 357(7):713; author reply 714-5. PubMed ID: 17703527
    [No Abstract]   [Full Text] [Related]  

  • 28. Clinical strategies to address patients' concerns in osteoporosis management with bisphosphonates.
    Cole RE
    Postgrad Med; 2011 Mar; 123(2):131-44. PubMed ID: 21474901
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ranking antireabsorptive agents to prevent vertebral fractures in postmenopausal osteoporosis by mixed treatment comparison meta-analysis.
    Migliore A; Broccoli S; Massafra U; Cassol M; Frediani B
    Eur Rev Med Pharmacol Sci; 2013 Mar; 17(5):658-67. PubMed ID: 23543450
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In postmenopausal women with osteoporosis, is zoledronic acid (Reclast) superior in improving T-scores and decreasing fracture rates when compared with placebo?
    Bilbao J; Pugh A; Aspy CB
    J Okla State Med Assoc; 2010 Aug; 103(8):374-5. PubMed ID: 21049709
    [No Abstract]   [Full Text] [Related]  

  • 31. Ibandronate: is there an effect on nonvertebral fractures?
    Kastelan D; Korsic M; Vlak T
    Clin Rheumatol; 2008 Oct; 27(10):1313-5. PubMed ID: 18651099
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Persistence with bisphosphonate therapy in older people.
    Melo M; Qiu F; Sykora K; Juurlink D; Laupacis A; Mamdani M
    J Am Geriatr Soc; 2006 Jun; 54(6):1015-6. PubMed ID: 16776810
    [No Abstract]   [Full Text] [Related]  

  • 33. Treatments for osteoporosis - looking beyond the HORIZON.
    Compston J
    N Engl J Med; 2007 May; 356(18):1878-80. PubMed ID: 17476015
    [No Abstract]   [Full Text] [Related]  

  • 34. [Absolute risk for fracture and WHO guideline. Selection of drugs for the prevention of fractures in postmenopausal women].
    Gorai I;
    Clin Calcium; 2007 Jul; 17(7):1090-6. PubMed ID: 17607077
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Ibandronate in the treatment of postmenopausal osteoporosis].
    Lakatos P
    Lege Artis Med; 2008 Oct; 18(10):657-61. PubMed ID: 19227607
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Once-monthly dosing: an effective step forward.
    Reid DM
    Bone; 2006 Apr; 38(4 Suppl 1):S18-22. PubMed ID: 16533625
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bisphosphonate dose and incidence of fractures in postmenopausal osteoporosis.
    Makras P; Hamdy NA; Zwinderman AH; Ballieux BE; Papapoulos SE
    Bone; 2009 May; 44(5):766-71. PubMed ID: 19442613
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lasofoxifene: new drug. Osteoporosis: no better than raloxifene.
    Prescrire Int; 2009 Dec; 18(104):247. PubMed ID: 20020572
    [No Abstract]   [Full Text] [Related]  

  • 39. Yearly zoledronic acid in postmenopausal osteoporosis.
    de Nijs RN; Westgeest AA
    N Engl J Med; 2007 Aug; 357(7):711; author reply 714-5. PubMed ID: 17699824
    [No Abstract]   [Full Text] [Related]  

  • 40. Going on a drug holiday?
    Bonnick SL
    J Clin Densitom; 2011; 14(4):377-83. PubMed ID: 22051091
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.